Literature DB >> 22076652

Genetic alterations of PTEN in human melanoma.

Almass-Houd Aguissa-Touré1, Gang Li.   

Abstract

The PTEN gene is one of the most frequently inactivated tumor suppressor genes in sporadic cancers. Inactivating mutations and deletions of the PTEN gene are found in many types of cancers, including melanoma. However, the exact frequency of PTEN alteration in melanoma is unknown. In this study, we comprehensively reviewed 16 studies on PTEN genetic changes in melanoma cell lines and tumor biopsies. To date, 76 PTEN alterations have been reported in melanoma cell lines and 38 PTEN alterations in melanoma biopsies. The rate of PTEN alterations in melanoma cell lines, primary melanoma, and metastatic melanoma is 27.6, 7.3, and 15.2%, respectively. Three mutations were found in both melanoma cell lines and biopsies. These mutations are scattered throughout the gene, with the exception of exon 9. A mutational hot spot is found in exon 5, which encodes the phosphatase activity domain. Evidence is also presented to suggest that numerous homozygous deletions and missense variants exist in the PTEN transcript. Studying PTEN functions and implications of its mutations and other genes could provide insights into the precise nature of PTEN function in melanoma and additional targets for new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076652     DOI: 10.1007/s00018-011-0878-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  149 in total

1.  Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

Authors:  M M Georgescu; K H Kirsch; P Kaloudis; H Yang; N P Pavletich; H Hanafusa
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

2.  A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.

Authors:  G A Rodrigues; M Falasca; Z Zhang; S H Ong; J Schlessinger
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 3.  Faithfull modeling of PTEN loss driven diseases in the mouse.

Authors:  Caterina Nardella; Arkaitz Carracedo; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

4.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.

Authors:  P L Dahia; D J Marsh; Z Zheng; J Zedenius; P Komminoth; T Frisk; G Wallin; R Parsons; M Longy; C Larsson; C Eng
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

5.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

6.  Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Authors:  Min Sup Song; Arkaitz Carracedo; Leonardo Salmena; Su Jung Song; Ainara Egia; Marcos Malumbres; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-01-21       Impact factor: 41.582

7.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

8.  Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia.

Authors:  A H Parmiter; G Balaban; W H Clark; P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1988-02

9.  Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.

Authors:  L Liu; N J Lassam; J M Slingerland; D Bailey; D Cole; R Jenkins; D Hogg
Journal:  Oncogene       Date:  1995-07-20       Impact factor: 9.867

10.  Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.

Authors:  L Davidson; H Maccario; N M Perera; X Yang; L Spinelli; P Tibarewal; B Glancy; A Gray; C J Weijer; C P Downes; N R Leslie
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more
  46 in total

1.  Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.

Authors:  M Corazzari; F Rapino; F Ciccosanti; P Giglio; M Antonioli; B Conti; G M Fimia; P E Lovat; M Piacentini
Journal:  Cell Death Differ       Date:  2014-11-07       Impact factor: 15.828

2.  Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Authors:  Nilanjana Chatterjee; Evangelos Pazarentzos; Manasi K Mayekar; Philippe Gui; David V Allegakoen; Gorjan Hrustanovic; Victor Olivas; Luping Lin; Erik Verschueren; Jeffrey R Johnson; Matan Hofree; Jenny J Yan; Billy W Newton; John V Dollen; Charles H Earnshaw; Jennifer Flanagan; Elton Chan; Saurabh Asthana; Trey Ideker; Wei Wu; Junji Suzuki; Benjamin A Barad; Yuriy Kirichok; James S Fraser; William A Weiss; Nevan J Krogan; Asmin Tulpule; Amit J Sabnis; Trever G Bivona
Journal:  Cell Rep       Date:  2019-08-27       Impact factor: 9.423

3.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

4.  CTGF is a therapeutic target for metastatic melanoma.

Authors:  E C Finger; C-F Cheng; T R Williams; E B Rankin; B Bedogni; L Tachiki; S Spong; A J Giaccia; M B Powell
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

5.  Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.

Authors:  Wei-Zhong Xiao; Dong-Hua Han; Fei Wang; Yong-Qian Wang; You-Hou Zhu; Yi-Fang Wu; Ning-Tao Liu; Ji-Yong Sun
Journal:  Tumour Biol       Date:  2014-04-08

6.  Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.

Authors:  Meng-Hua Dong; Qian Zhang; Yuan-Yuan Wang; Bai-Sui Zhou; Yu-Fei Sun; Qiang Fu
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

Review 7.  Interaction of molecular alterations with immune response in melanoma.

Authors:  Robert A Szczepaniak Sloane; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Xue Zhang; Alexandre Reuben; Jennifer A Wargo
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

Review 8.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

9.  The antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradation.

Authors:  Ida Aronchik; Aishwarya Kundu; Jeanne G Quirit; Gary L Firestone
Journal:  Mol Cancer Res       Date:  2014-07-09       Impact factor: 5.852

10.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.